In this recent study,1 the authors analyzed the metabolic gene essentiality scores from genome-wide loss of function CRISPR screens in 769 human cancer cell lines and noticed that TCA cycle-associated genes clustered in two separate groups: one forming the traditional TCA cycle and another related to a non-canonical TCA cycle module. They monitored both modules with elegant tracing studies using [U-13C]glucose which generates citrate labeled with two 13C atoms (M+2).

L'extraction par CO2 supercritique démontre les avantages d'un procédé de chimie verte en comparant ce procédé à la méthode d'extraction par solvant organiques et en tenant compte du degré de toxicité et de pollution du solvant. L'extraction par solvants organiques met en évidence l'influence du solvant d'extraction alors que l'extraction par CO2-SC met en évidence l'influence de différents paramètres dont la pression, la température, le temps de contact entre la matrice végétale et le CO2-SC, le diamètre moyen des particules et l'ajout d'un co-solvant. L'analyse chromatographique a permis d'identifier et de quantifier les flavonolignanes (silychristine, silydianine, silybine, taxifoline) dans les extraits de graines obtenus par solvants organiques et par CO2-SC avec co-solvant. A 220 bar, les concentrations en silydianine (38,87 mg/g) et en silybine (45,91mg/g) sont les plus élevés et à 40°C les concentrations en silychristine (31,97mg/g), en silydianine (38,87 mg/g) et en silybine (45,91mg/g) sont les plus importantes. Les extraits huileux obtenus à 220 bar et à 40°C des graines de Silybum marianum sont riches en acides gras : acide linoléique (65,22%), acide oléique (27,01%), acide palmitique (12,12%). L'activité antioxydante a été évaluée par deux tests : test DPPH et test ABTS. Ces deux tests sont complémentaires et ont permis de conclure que l'extrait ayant un effet antioxydant le plus important est l'extrait obtenu par CO2-SC à 220 bar et à 40°C. L'activité biologique de cet extrait est mise en évidence par rapport à une lignée cellulaire cancéreuse du colon Caco-2. La silychristine, la silydianine et la silybine ainsi que l'extrait obtenu par CO2-SC avec co-solvant (éthanol) à 220 bar et à 40°C ont été testés vis à vis de cette lignée cancéreuse. Ces expérimentations in vitro reflètent une activité cytotoxique quantifiable et une mortalité cellulaire des Caco-2 des flavonolignanes allant jusqu'à 71% / The supercritical CO2 extraction demonstrates the benefits of green chemistry process comparing with the method of organic solvents extraction and depending to toxicity and pollution solvent degree. Organic solvents extraction shows the solvent extraction influence, so that the SC-CO2 extraction highlights different parameters including pressure, temperature, contact time between the plant matrix and CO2 SC, the average particle diameter and the addition of a cosolvent. Chromatographic analysis identified and quantified four flavonolignans (silychristin, silydianin, silybin, taxifolin) in seed extracts obtained by organic solvents and SC-CO2 with cosolvent. At 220 bar, silydianin (38.87 mg / g) and silybin (45.91 mg / g) have highest concentrations and at 40°C silychristin (31.97 mg / g), silydianin (38.87 mg / g) and silybin (45.91 mg / g) have the most important concentrations. The oily extracts obtained at 220 bar and 40°C of Silybum marianum seeds are rich in fatty acids: linoleic acid (65.22%), oleic acid (27.01%), palmitic acid (12.12%). The antioxidant activity measured by two tests: DPPH and ABTS test. These two tests are complementary and confirm that the extract with the higher antioxidant effect is the extract obtained by SC-CO2 at 220 bar and 40°C. The biological activity of this extract is demonstrated with respect to a colon cancer cell line Caco-2. Silychristin, silydianin and silybin and the extract obtained by CO2-SC with co-solvent (ethanol) at 220 bar and 40°C were tested with respect to this line cancer. These experiments in vitro cytotoxic activity reflect estimable and cell death of Caco-2 flavonolignans of up to 71%

Le sarcome de Ewing est la seconde tumeur pédiatrique de l’os la plus fréquente. Elle est caractérisée par une translocation chromosomique résultant à la fusion de EWSR1 avec un membre de la famille ETS. Chez 85% des patients, cette fusion conduit à l’expression de la protéine chimérique EWS-FLI1 qui est l’oncogène majeur de ce sarcome. Ce dernier agit principalement par son action transcriptionelle sur des cibles qui lui sont propres. Au niveau thérapeutique, le sarcome d’Ewing est traité par chimiothérapie, chirurgie locale et par radiothérapie. La survie à long terme des patients est de l’ordre de 70%, mais beaucoup plus basse pour les patients métastatiques et quasi nulle lors d’une récidive. Parmi maintes caractéristiques, certains cancers présentent une dérégulation énergétique. L’influence d’EWS-FLI1 sur cet aspect n’a fait l’objet d’aucune étude dans le contexte du sarcome d’Ewing. Nous avons donc étudié par profilage métabolomique des cellules de sarcome d’Ewing en présence ou en absence d’EWS-FLI1. En comparant ces deux conditions, des modulations du profil énergétique relatif au cycle de Krebs, des précurseurs de le glycosylation ainsi que des métabolites de la voie de la méthionine et du tryptophane ont été observés. En parallèle, grâce à un crible de banque de shRNAs réalisé dans des conditions expérimentales similaires à l’étude métabolomique (lignée d’Ewing avec ou sans EWS-FLI1), nous avons pu identifier des gènes présentant des caractéristiques « synthétique létales », c'est-à-dire tuant uniquement les cellules du sarcome d’Ewing en présence de son oncogène. / Ewing sarcoma, the second most commonly occurring pediatric bone tumor, is most often characterized by a chromosomal translocation between EWSR1 and FLI1. The gene fusion EWS-FLI1 accounts for 85% of all Ewing sarcoma and is considered the major oncogene and master regulator of Ewing sarcoma. EWS-FLI1 is a transcriptional modulator of targets, both directly and indirectly. Ewing sarcoma is aggressively treated with chemotherapy, localized surgery and radiation and has an overall survival of about 70%, however, survival for metastasis or relapsed cases remains low. One of the cancer hallmarks, metabolic deregulation, is most likely partly dependent on EWS-FLI1 in Ewing sarcoma cells. In order to get a better understanding of Ewing sarcoma biology and oncogenesis, it might be of high interest to investigate the influence of EWS-FLI1 in Ewing sarcoma cells. We therefore performed a global metabolic profiling of Ewing sarcoma cells with or without inhibition of EWS-FLI1. Several changes in the energy metabolism were observed throughout this study; the observed changes were consistent with an energy profile that moved from a cancer cell energy metabolism towards the energy metabolism of a more normal cell upon EWS-FLI1 inhibition, primarily based on the TCA cycle. Levels of TCA intermediates, glycosylation precursors, methionine pathway metabolites and amino acids, especially changes in the tryptophan metabolic pathway, were altered upon EWS-FLI1 inhibition. Parallel to this study, we performed a high-throughput synthetic lethality screen, in order to not only identify essential genes for cell survival and proliferation, but also to identify new synthetic lethal targets that could specifically target Ewing sarcoma cells carrying the EWS-FLI1 fusion gene.

Cancer progression is a multi-step process requiring cells to acquire specific properties that aid the neoplastic growth. One such property is the ability to survive in the absence of matrix-attachment, a critical necessity for cells to traverse in circulation and seed metastases. Therefore, understanding the signalling mechanisms that protect cells from undergoing death in matrix-deprived condition, termed as anoikis, is important. We have used two systems to study this, one involving experimental transformation model, and another involving cancer cell lines. In the in vitro transformation model system involving the serial introduction of oncogenes, the ability to survive in anchorage-independent condition and generate spheres/colonies was dependent on the presence of the Simian Virus Small T antigen, SV40 ST. We identified that the viral antigen mediates its effects, at least in part, by activating the master metabolic regulator and cellular stress kinase AMP-activated protein kinase (AMPK) leading to maintenance of energy homeostasis. Consistent with this, our lab has previously identified both activation of AMPK upon matrix-deprivation in breast cells, as well as its requirement for survival under these conditions. However, a pathway often associated with survival under matrix-deprivation is the PI3K/Akt pathway. Surprisingly, we observed an AMPK-dependent decrease in Akt activity under conditions of matrix-detachment. Since this was contrary to the general notion, we probed deeper into a possible crosstalk between these two kinases. Our work revealed that AMPK activation in suspension inhibits Akt via upregulation of a known Akt phosphatase, pleckstrin homology domain leucinrich repeat protein phosphatise (PHLPP). We further show that the AMPK-PHLPP-Akt signalling axis is important for anoikis-resistance and metastasis. In addition, our results point to a yet unidentified protumorigenic role of PHLPP in breast cancer progression. With an aim to identify cellular proteins differentially regulated upon AMPK activation in breast cancer cells, we undertook a proteomics approach. Using 2-dimensional gel electrophoresis followed by mass spectrometric analysis, we identified some candidate proteins. We have validated the increase in levels of one of these proteins, annexin A2, in cancer cells upon AMPK activation. In summary, the present study unveils novel oncogenic functions of AMPK in cancer cells under the stress of matrix-deprivation. Furthermore, our results elucidate a double-negative feedback loop between two critical cellular kinases AMPK and Akt, and also identify a novel pro-tumorigenic role of PHLPP in breast cancer. In addition, we identify PHLPP and annexin A2 as novel proteins upregulated by AMPK in cancer cells. Thus, our results begin to identify pathways utilised by cancer cells to aid anchorage-independent growth, a critical step for cancer metastasis. Based on our results, inhibition of AMPK or perturbation of signalling axes involving AMPK, and PHLPP or annexin A2 might be considered as novel therapeutic approaches to combat cancer progression

No description available.

No description available.

The thesis deals with the natural substances in context with the cancer disease. The natural substances have a positive effect on the human organism and they are able to influence the viability and the growth of the cancer cells. The main mechanical device is to influence the mechanisms needed to start the apoptosis of the cancer cells and stopping further proliferation. The cancer cell lines utilization in the cancer disease is discussed in the thesis too. The thesis states common methods of determining the natural substances cytotoxicity. For the experimental part of the thesis it was chosen the MTT test method and the xCELLigence system for monitoring in real time. The mechanical device of the tested substance capsaicin in application on the prostate cell lines, tumorous PC3 and nontumorous PNT1A influence will be observed within the experimental part of the thesis.

Despite advances in cancer diagnosis and therapy, cancer is the second leading cause of death globally. The improvements of cancer treatment are the major challenge in this research. The aim of the thesis was studying of effects of two anticancer drugs ellipticine (Elli) and doxorubicin (DOX) on some cancer and healthy cell lines. Specific consideration was given to expand current knowledge about the metabolism and cytostatic effects of Elli in neuroblastoma cell lines. Another part of this study was focused on mechanisms contributing to the development of ellipticine-resistance in cancer cells and influence of histone deacetylase inhibitors on anticancer therapy was investigated. Moreover, the aim was to develop apoferritin (Apo) nanocarrier suitable for the active transport of cytostatics to cancer cells. Several essential data were found in this doctoral thesis. Anticancer efficiency of Elli depends on the CYP3A4-mediated metabolism in cancer. The CYP3A4 enzyme encapsulated into two nanoparticle forms, liposomes and SupersomesTM , was tested to activate ellipticine to its reactive species forming covalent DNA adducts. The formation of adducts seems to be dependent on concentrations of CYP3A4 in nanoparticle systems. A higher effectiveness of CYP3A4 in SupersomesTM than in liposomes to form...

Das Harnblasenkarzinom (BCa) ist die zweithäufigste bösartige urologische Tumorerkrankung sowie die siebthäufigste tumorbedingte Todesursache bei Männern. Zur Senkung des erheblichen Rezidiv- und Progressionsrisikos oberflächlicher BCa kommen lokale Immun- oder Chemotherapeutika zum Einsatz, die jedoch starke Nebenwirkungen verursachen können bzw. ungenügende langfristige Effekte bewirken. Eine neuartige Therapieoption besteht in der gezielten Expressionshemmung von Genen, die den Tumorzellen einen Wachstumsvorteil vermitteln. Hierfür eignen sich besonders synthetische Nukleinsäuren wie Antisense-Oligodesoxynukleotide (AS-ODN) und small interfering RNAs (siRNAs). In der vorliegenden Arbeit wurde die Expressionshemmung des potenziellen Targetgens hTERT (humane Telomerase Reverse Transkriptase) mit AS-ODN und siRNAs in BCa-Zellen untersucht. Die Tumorspezifität der hTERT-mRNA-Expression konnte zunächst an tumor- und tumorfreien Gewebeproben von BCa-Patienten gezeigt werden. Die verwendeten AS-ODN reduzierten die hTERT-mRNA-Expression auf bis zu 40%, womit eine Verringerung der Telomeraseaktivität einherging. Die AS-ODN-Behandlung bewirkte des Weiteren eine konzentrationsabhängige Viabilitätsreduktion verschiedener BCa-Zelllinien sowie eine verminderte Zellkoloniebildungsrate. Diese antiproliferativen Effekte waren auf eine Apoptoseinduktion zurückzuführen. Durch eine Vorbehandlung von vier BCa-Zelllinien mit hTERT-AS-ODN konnten die zytotoxischen Effekte der für das BCa relevanten Chemotherapeutika Cisplatin, Mitomycin C und Gemcitabin signifikant verstärkt werden. Nach Untersuchung der AS-ODN-Wirkung in vitro erfolgte die Etablierung eines subkutanen Xenotransplantantmodells der Nacktmaus. Die Eignung einer intraperitonealen Applikation wurde mit fluoreszenzmarkierten AS-ODN belegt. In weiteren Zellkulturexperimenten kamen hTERT-siRNAs, als alternative Methode der Geninhibition, zum Einsatz. Die Reduktion der hTERT-mRNA-Expression auf 50% war mit der durch AS-ODN bewirkten Inhibition vergleichbar. Im Gegensatz zur AS-ODN-Behandlung induzierten siRNAs keine unmittelbare Apoptose. Eine Kombination der siRNAs mit Cisplatin und Mitomycin C bewirkte jedoch eine Verdopplung der Apoptoserate. Um die molekularen Mechanismen der Wirkung der nukleinsäurebasierten hTERT-Inhibitoren und den Einfluss targetunabhängiger Effekte zu untersuchen, wurden transkriptomweite Expressionsanalysen mittels Oligonukleotid-Microarrays durchgeführt. Hierbei zeigte sich, dass die AS-ODN-Behandlung vorwiegend zu einer gesteigerten Expression von Genen führte, die mit einer zellulären Stressantwort assoziiert sind (u.a. ATF3, EGR1, GADD45). Diese Expressionsmuster stimmten in hohem Maße mit denen überein, die durch Transfektion mit AS-ODN gegen andere Targets erhalten wurden. Diese Ergebnisse deuten auf eine, zumindest teilweise, durch off-Targeteffekte ausgelöste Wachstumshemmung hin. Die siRNA-Behandlungen gegen unterschiedliche Targets zeigten relativ geringe Übereinstimmungen in den Expressionsmustern und somit eine höhere Spezifität. Außerdem wurde erstmalig gezeigt, dass eine hTERT-Inhibition mit siRNAs zur trankriptionellen Hemmung der Onkogene EGFR und FOSL1 führt. Diese Daten sowie die Ergebnisse anderer Arbeitsgruppen deuten auf einen wechselseitigen Zusammenhang zwischen hTERT und EGFR in der Regulation der EGFR-stimulierten Proliferation von BCa-Zellen hin. Zusammenfassend lässt sich feststellen, dass hTERT als tumorspezifisch exprimierter und funktionell relevanter Faktor ein hervorragendes Target für eine nukleinsäurebasierte BCa-Therapieoption darstellt. Im Vergleich zu AS-ODN wirken siRNAs grundsätzlich targetspezifischer. Die therapeutische Wertigkeit der lokal applizierten Inhibitoren, insbesondere in Kombination mit herkömmlichen Chemotherapeutika, sollte in nachfolgenden Experimenten im Rahmen eines orthotopen BCa-Xenotransplantatmodells untersucht werden.

No description available.